Search

Displaying results 6851 - 6860 of 8410 in total
  1. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  2. Drug

    Alteminostat

    go.drugbank.com/drugs/DB19620
    Investigational

    Alteminostat has a monoisotopic molecular weight of 492.28 Da.

  3. Drug

    Gemilukast

    go.drugbank.com/drugs/DB19882
    Investigational

    Gemilukast has a monoisotopic molecular weight of 601.26 Da.

  4. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant has a monoisotopic molecular weight of 446.25 Da.

  5. Drug

    Idetrexed

    go.drugbank.com/drugs/DB21469
    Investigational

    Idetrexed has a monoisotopic molecular weight of 647.22 Da.

  6. Drug

    Sodium zirconium cyclosilicate

    go.drugbank.com/drugs/DB14048
    ApprovedInvestigational

    Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that

  7. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

  8. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 8 AG
  9. Drug

    Hygromycin B

    go.drugbank.com/drugs/DB11520
    ExperimentalVet approved

    Hygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.

  10. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).